Kymera Historical Income Statement

KYMR Stock

USD 46.86 0.88 1.91%

Historical analysis of Kymera Therapeutics income statement accounts such as Interest Expense of 132.7 K can show how well Kymera Therapeutics performed in making a profits. Evaluating Kymera Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Kymera Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Kymera Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kymera Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.

About Kymera Income Statement Analysis

Kymera Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Kymera Therapeutics shareholders. The income statement also shows Kymera investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Kymera Therapeutics Income Statement Chart

At this time, Kymera Therapeutics' Net Interest Income is relatively stable compared to the past year. As of 11/29/2024, Interest Income is likely to grow to about 19.7 M, while Interest Expense is likely to drop slightly above 132.7 K.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses Net Income Applicable To Common Shares

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Kymera Therapeutics. It is also known as Kymera Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from Kymera Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Kymera Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.At this time, Kymera Therapeutics' Net Interest Income is relatively stable compared to the past year. As of 11/29/2024, Interest Income is likely to grow to about 19.7 M, while Interest Expense is likely to drop slightly above 132.7 K.

	2021	2022	2023	2024 (projected)
Interest Expense	175K	176K	196K	132.7K
Depreciation And Amortization	2.4M	3.0M	3.6M	2.3M

Interest Expense Depreciation And Amortization

Kymera Therapeutics income statement Correlations

	Net Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Gross Profit	Cost Of Revenue	Income Tax Expense	Non Operating Income Net Other
Net Interest Income		0.72	0.68	0.75	0.74	-0.86	-0.82	-0.82	0.73	-0.82	0.74	0.73	-0.82	1.0	-0.83	-0.8	0.95	0.93	0.94
Depreciation And Amortization	0.72		0.96	0.95	0.95	-0.93	-0.93	-0.93	0.95	-0.93	0.95	0.98	-0.93	0.72	-0.93	-0.33	0.64	0.5	0.76
Interest Expense	0.68	0.96		0.98	0.98	-0.92	-0.93	-0.93	0.98	-0.93	0.98	0.99	-0.93	0.68	-0.93	-0.24	0.61	0.44	0.72
Selling General Administrative	0.75	0.95	0.98		1.0	-0.95	-0.96	-0.96	1.0	-0.96	1.0	0.99	-0.96	0.75	-0.96	-0.31	0.65	0.53	0.8
Other Operating Expenses	0.74	0.95	0.98	1.0		-0.96	-0.96	-0.96	1.0	-0.96	1.0	0.99	-0.96	0.74	-0.96	-0.28	0.63	0.51	0.79
Operating Income	-0.86	-0.93	-0.92	-0.95	-0.96		1.0	1.0	-0.96	1.0	-0.96	-0.94	1.0	-0.86	1.0	0.41	-0.72	-0.63	-0.91
Net Income From Continuing Ops	-0.82	-0.93	-0.93	-0.96	-0.96	1.0		1.0	-0.96	1.0	-0.96	-0.95	1.0	-0.82	1.0	0.35	-0.68	-0.59	-0.89
Ebit	-0.82	-0.93	-0.93	-0.96	-0.96	1.0	1.0		-0.96	1.0	-0.96	-0.95	1.0	-0.82	1.0	0.35	-0.68	-0.59	-0.89
Research Development	0.73	0.95	0.98	1.0	1.0	-0.96	-0.96	-0.96		-0.96	1.0	0.99	-0.96	0.73	-0.96	-0.27	0.62	0.5	0.79
Ebitda	-0.82	-0.93	-0.93	-0.96	-0.96	1.0	1.0	1.0	-0.96		-0.96	-0.95	1.0	-0.82	1.0	0.35	-0.68	-0.59	-0.89
Total Operating Expenses	0.74	0.95	0.98	1.0	1.0	-0.96	-0.96	-0.96	1.0	-0.96		0.99	-0.96	0.74	-0.96	-0.28	0.63	0.51	0.79
Reconciled Depreciation	0.73	0.98	0.99	0.99	0.99	-0.94	-0.95	-0.95	0.99	-0.95	0.99		-0.95	0.73	-0.95	-0.32	0.66	0.5	0.78
Income Before Tax	-0.82	-0.93	-0.93	-0.96	-0.96	1.0	1.0	1.0	-0.96	1.0	-0.96	-0.95		-0.82	1.0	0.35	-0.68	-0.59	-0.89
Total Other Income Expense Net	1.0	0.72	0.68	0.75	0.74	-0.86	-0.82	-0.82	0.73	-0.82	0.74	0.73	-0.82		-0.83	-0.8	0.95	0.93	0.94
Net Income	-0.83	-0.93	-0.93	-0.96	-0.96	1.0	1.0	1.0	-0.96	1.0	-0.96	-0.95	1.0	-0.83		0.36	-0.69	-0.6	-0.9
Gross Profit	-0.8	-0.33	-0.24	-0.31	-0.28	0.41	0.35	0.35	-0.27	0.35	-0.28	-0.32	0.35	-0.8	0.36		-0.9	-0.91	-0.63
Cost Of Revenue	0.95	0.64	0.61	0.65	0.63	-0.72	-0.68	-0.68	0.62	-0.68	0.63	0.66	-0.68	0.95	-0.69	-0.9		0.95	0.81
Income Tax Expense	0.93	0.5	0.44	0.53	0.51	-0.63	-0.59	-0.59	0.5	-0.59	0.51	0.5	-0.59	0.93	-0.6	-0.91	0.95		0.78
Non Operating Income Net Other	0.94	0.76	0.72	0.8	0.79	-0.91	-0.89	-0.89	0.79	-0.89	0.79	0.78	-0.89	0.94	-0.9	-0.63	0.81	0.78

Click cells to compare fundamentals

Kymera Therapeutics Account Relationship Matchups

Kymera Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Net Interest Income	959K	711K	313K	6.4M	18.6M	19.5M
Interest Income	1.0M	826K	488K	6.6M	18.8M	19.7M
Depreciation And Amortization	1.8M	1.8M	2.4M	3.0M	3.6M	2.3M
Interest Expense	46K	115K	175K	176K	196K	132.7K
Selling General Administrative	8.0M	18.2M	36.3M	43.8M	55.0M	30.3M
Total Revenue	2.9M	34.0M	72.8M	46.8M	78.6M	43.1M
Other Operating Expenses	45.1M	80.3M	173.4M	208.1M	244.1M	141.6M
Operating Income	(42.2M)	(46.3M)	(100.5M)	(161.3M)	(165.5M)	(157.3M)
Net Income From Continuing Ops	(41.2M)	(45.6M)	(100.2M)	(154.8M)	(147.0M)	(139.6M)
Ebit	(42.2M)	(45.5M)	(100.0M)	(154.6M)	(146.8M)	(139.4M)
Research Development	37.2M	62.1M	137.0M	164.2M	189.1M	111.3M
Ebitda	(40.4M)	(43.7M)	(97.6M)	(151.7M)	(143.2M)	(136.0M)
Total Operating Expenses	45.1M	80.3M	173.4M	208.1M	244.1M	141.6M
Reconciled Depreciation	825K	1.8M	2.4M	3.0M	3.6M	2.2M
Income Before Tax	(41.2M)	(45.6M)	(100.2M)	(154.8M)	(147.0M)	(139.6M)
Total Other Income Expense Net	959K	711K	313K	6.4M	18.6M	19.5M
Net Income Applicable To Common Shares	(41.2M)	(54.6M)	(100.2M)	(154.8M)	(139.3M)	(132.4M)
Net Income	(41.3M)	(43.9M)	(98.0M)	(151.8M)	(147.0M)	(139.6M)

Pair Trading with Kymera Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.

The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Kymera Stock Analysis

When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kymera Historical Income Statement

About Kymera Income Statement Analysis

Kymera Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Net Income Applicable To Common Shares

Kymera Therapeutics income statement Correlations

Kymera Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kymera Therapeutics income statement Accounts

Pair Trading with Kymera Therapeutics

Additional Tools for Kymera Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Other Income Expense Net	+ 1.0	Net Interest Income
Other Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Selling General Administrative
Total Operating Expenses	+ 1.0	Selling General Administrative
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses

Net Income	- 0.96	Total Operating Expenses
Income Before Tax	- 0.96	Total Operating Expenses
Total Operating Expenses	- 0.96	Ebitda
Net Income	- 0.96	Research Development
Income Before Tax	- 0.96	Research Development
Ebitda	- 0.96	Research Development